English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Wanbang to Begin Clinical Trial of Fast-Acting Insulin Analogue

Sep. 16, 2013

Wanbang Biopharmaceuticals, a subsidiary of Shanghai Fosun Pharma, received CFDA clearance to begin clinical trials of a third-generation insulin analogue, Lispro. Lispro is a recombinant insulin that is designed to be fast-acting, with a relatively short duration of action, usually taken just before, or just after mealtimes. In China, only Lilly and Gan & Lee offer Lispro-class insulin drugs.